Jianping He

This study identifies TRAIL as a synthetic essentiality in VHL-deficient ccRCC, showing its regulation by HIF2 and its role in cell proliferation through the p38 MAPK pathway, suggesting a combination therapy strategy.

This study recharacterizes RSL3 as a broad selenoprotein inhibitor, showing its potential as a therapeutic target for colorectal cancer by inducing ferroptosis.

The paper shows cell cycle arrest increases sensitivity to GPX4 inhibitor-induced ferroptosis via elevated oxidizable phospholipids and reduced EMP2 expression.